Somerset Pharma expands generic portfolio

Somerset Pharma is launching six new generic products. The medications include:

• Acetylcysteine Injection 200mg/ml, 30ml vial, which is the generic of Acetadote. The product is indicated for acute acetaminophen toxicity.
• Cupric Chloride Injection, 0.4mg/ml, 10ml vial, which is the generic of Copper, and indicated for Total Parenteral Nutrition Supplement.
• Hydroxyurea Capsules, 500 mg, 100 capsules, which is the generic of Hydrea. It is indicated to Chronic Myeloid Leukemia and locally advanced squamous cell carcinomas of the head and neck in combination with chemoradiation.
• Midazolam Injection, 1mg/ml, 2ml and 5ml vial, the generic of Versed, an indication of general anesthesia and preoperative sedation, anxiolysis and amnesia.
• Potassium Phosphates Injection, 3 mmol/ml & 4.4 mEq/ml, 5ml and 15ml vial. The indication is for hypophosphatemia and parenteral nutrition.
• Timolol Maleate Ophthalmic Solution, 0.25% and 0.5%, which is the generic of Timpotic. The indication is for the treatment of ocular hypertension and open-angle glaucoma.

[Read more: Generic drug makers continue forging ahead]

“The launch of six new products in quick succession demonstrates our commitment to research and development, as well as our dedication to maintaining a robust product pipeline. This consistent effort ensures that we can offer a portfolio that meets the industry’s demand for high-quality generic suppliers,” said Veerappan Subramanian, chairman and CEO of Somerset Pharma.